Praxis Medical Insights

Diagnostic Evaluation Before Treatment

The European Urology guideline recommends completing a thorough medical history focusing on symptom duration, severity, associated symptoms, and previous episodes to rule out infectious causes 1
A physical examination including evaluation of the suprapubic area, external genitalia, and digital rectal examination should be performed to assess prostate size and tenderness, as recommended by the European Association of Urology 1
Urinalysis and urine culture should be obtained to definitively rule out infectious causes, according to the European Urology guideline 1
A validated symptom score questionnaire such as the International Prostate Symptom Score (IPSS) should be used to assess symptom severity and bother, as recommended by the European Association of Urology 4
A frequency-volume chart should be completed for at least 3 days, especially when nocturia is a prominent symptom, as suggested by the European Urology guideline 4
Post-void residual volume should be measured to evaluate for urinary retention, as recommended by the European Association of Urology 1
Uroflowmetry should be considered before initiating treatment to establish baseline parameters, according to the European Urology guideline 1

The European Association of Urology recommends alpha-1 adrenoceptor antagonists (α1-blockers) such as tamsulosin or alfuzosin as the first-line treatment for non-infectious dysuria in men, due to their rapid onset of action, good efficacy, and low rate of adverse events 1
These medications work by relaxing smooth muscle in the prostate and bladder neck, improving urinary flow, as explained by the European Urology guideline 1
Efficacy should be assessed after 2-4 weeks of treatment, according to the European Association of Urology 3
Common side effects of alpha-blockers include asthenia, dizziness, and orthostatic hypotension, as reported by the European Urology guideline 1
For men with prostate enlargement, the European Association of Urology suggests considering adding 5α-reductase inhibitors (5-ARIs) such as finasteride or dutasteride to the α1-blocker, as this combination is more effective for long-term symptom management and reducing disease progression in men with larger prostates 1
For men with predominant storage symptoms, the European Urology guideline recommends considering anticholinergics or beta-3 agonists, but caution is needed when using anticholinergics in men with elevated post-void residual volumes 1
For men with concurrent erectile dysfunction, the European Association of Urology suggests considering phosphodiesterase-5 inhibitors (PDE5i) such as tadalafil, which can address both LUTS and erectile dysfunction 3

The European Urology guideline recommends evaluating patients 4-12 weeks after initiating treatment to assess response, and assessment should include symptom evaluation using standardized questionnaires like IPSS 1
Post-void residual volume should be measured at follow-up to monitor for urinary retention, as recommended by the European Association of Urology 3
Annual follow-up is recommended for stable patients to monitor for symptom progression, according to the European Urology guideline 3

Men with findings suspicious for prostate cancer, hematuria, abnormal PSA, recurrent symptoms, or neurological disease should be referred to a urologist, as recommended by the European Association of Urology 2
Alpha-blockers may cause ejaculatory dysfunction, particularly selective α1-blockers like tamsulosin and silodosin, as reported by the European Urology guideline 1
Men on α1-blockers who are scheduled for cataract surgery are at increased risk of intraoperative floppy iris syndrome, as warned by the European Urology guideline 1
Self-management, including education, reassurance, periodic monitoring, and lifestyle advice, should be included in the management plan, as recommended by the European Association of Urology 1

Failing to rule out infectious causes before initiating treatment for non-infectious dysuria, as cautioned by the European Association of Urology 2
Not considering prostate size when selecting treatment, as α1-blockers alone are more effective for smaller prostates <40 ml, as recommended by the European Urology guideline 1
Treating symptoms without addressing the underlying condition, as warned by the European Association of Urology 5
Initiating anticholinergics in men with significant post-void residual volumes, as cautioned by the European Urology guideline 1